Compugen Company Profile (NASDAQ:CGEN)

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. Compugen had a negative net margin of 4,425.00% and a negative return on equity of 47.40%. View Compugen's Earnings History.

1 brokerages have issued twelve-month price targets for Compugen's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Compugen's share price to reach $14.00 in the next twelve months. View Analyst Ratings for Compugen.

Here are some recent quotes from research analysts about Compugen stock:

• 1. According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (5/22/2017)
• 2. FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

Some companies that are related to Compugen include Adamas Pharmaceuticals (ADMS), PDL BioPharma (PDLI), Abeona Therapeutics (ABEO), Concert Pharmaceuticals (CNCE), Celyad SA (CYAD), Novavax (NVAX), Idera Pharmaceuticals (IDRA), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Curis (CRIS), Advaxis (ADXS), Codexis (CDXS), Voyager Therapeutics (VYGR), Corvus Pharmaceuticals (CRVS), Horizon Discovery Group PLC (HZD), Zynerba Pharmaceuticals (ZYNE), Protagonist Therapeutics (PTGX) and NewLink Genetics Corporation (NLNK).

Compugen's management team includes the folowing people:

• Martin S. Gerstel, Chairman of the Board
• Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director
• Ari Krashin, Chief Financial Officer
• Zurit Levine Ph.D., Vice President - Research and Discovery
• John Hunter, Vice President - Antibody Research & Development
• Dov Hershberg, Director
• Michal Preminger Ph.D., Director
• Yair Aharonowitz Ph.D., Independent External Director
• Ruth Arnon, Independent Director
• Arie Ovadia, Independent External Director

Compugen's stock is owned by many different of institutional and retail investors. Top institutional investors include Rothschild Investment Corp IL (0.90%). View Institutional Ownership Trends for Compugen.

Compugen's stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL. View Insider Buying and Selling for Compugen.

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Compugen stock can currently be purchased for approximately $4.05.